ReviewAntibiotics (Basel, Switzerland)2019
An Approach to Measuring Colistin Plasma Levels Regarding the Treatment of Multidrug-Resistant Bacterial Infection.
Review in Antibiotics (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Advanced Biosensing Strategies for Last-Line Antibiotics Vancomycin, Colistin, Daptomycin and Meropenem: Comparative Analysis of Electrochemical and Optical Detection Methods.Antibiotics (Basel, Switzerland) · 2026Article
- Development of covalent inhibitors for bacterial histidine kinases.Chemical communications (Cambridge, England) · 2026Article
- Stability of Colistin Active Forms in Biological Matrices: Effect of Temperature and Time.European journal of drug metabolism and pharmacokinetics · 2026Article
- Multidrug-Resistant ESKAPEEc Pathogens From Bloodstream Infections in South Africa: A Cross-Sectional Study Assessing Resistance to WHO AWaRe Antibiotics.Health science reports · 2025Article
- Antimicrobial Resistance ofMicroorganisms · 2024Article
- Improving Photocleavage Efficiency of Photocleavable Protein for Antimicrobial Peptide Histatin 1 Expression.Protein and peptide letters · 2024Article
- Challenges of Colistin Use in ICU and Therapeutic Drug Monitoring: A Literature Review.Antibiotics (Basel, Switzerland) · 2023Review
- Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review-Part I.Antibiotics (Basel, Switzerland) · 2022Review
- A Retrospective Study of Risk Factors, Mortality, and Treatment Outcomes for Infections with Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2022Article
- Antimicrobial and Anti-Biofilm Activity of Polymyxin E Alone and in Combination with Probiotic Strains ofPathogens (Basel, Switzerland) · 2021Article
- Estimation of the Difference in Colistin Plasma Levels in Critically Ill Patients with Favorable or Unfavorable Clinical Outcomes.Pharmaceutics · 2021Article
- Broad-Spectrum Bactericidal Activity of a Synthetic Random Copolymer Based on 2-Methoxy-6-(4-Vinylbenzyloxy)-Benzylammonium Hydrochloride.International journal of molecular sciences · 2021Article
- Synthesis, Characterization, and Bactericidal Activity of a 4-Ammoniumbuthylstyrene-Based Random Copolymer.Polymers · 2021Article
- Emerging peptide antibiotics with therapeutic potential.Medicine in drug discovery · 2021Review
- Combining Colistin and Fluconazole Synergistically Increases Fungal Membrane Permeability and Antifungal Cidality.ACS infectious diseases · 2021Article
- Some Suggestions from PK/PD Principles to Contain Resistance in the Clinical Setting-Focus on ICU Patients and Gram-Negative Strains.Antibiotics (Basel, Switzerland) · 2020Review
- Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring.Journal of personalized medicine · 2020Review
- Is There a Role for the Therapeutic Drug Monitoring of Colistin? An Overview.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Antimicrobial resistance patterns and their encoding genes among clinical isolates ofMethodsX · 2020Article
- Optical Biosensors for Therapeutic Drug Monitoring.Biosensors · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Antimicrobial resistance to antibiotic treatment has significantly increased during recent years, causing this to become a worldwide public health problem. More than 70% of pathogenic bacteria are resistant to at least one of the currently used antibiotics. Polymyxin E (colistin) has recently been used as a "last line" therapy when treating Gram-negative multi-resistant bacteria. However, little is known about these molecules' pharmacological use as they have been discontinued because of their high toxicity. Recent research has been focused on determining colistimethate sodium's pharmacokinetic parameters to find the optimal dose for maintaining a suitable benefit-risk balance. This review has thus been aimed at describing the use of colistin on patients infected by multi-drug resistant bacteria and the importance of measuring this drug's plasma levels in such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.